Comparative In Vitro Activities of Fluconazole, Voriconazole, and MXP-4509 Against Romanian Blood Yeast Isolates

Mycopathologia

Volumn 172, Issue 6, 2011, Pages 487-492

  Mareş, Mihai ^a   Nǎstasǎ, Valentin ^a   Ramona, Florina Moraru ^a   Doroftei, Bogdan ^a,b   Ştefanache, Alina ^b  

^a UNIVERSITY OF AGRICULTURAL SCIENCES AND VETERINARY MEDICINE   (Romania)

^b GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Antifungal activity; Candida spp.; Fluconazole; MXP 4509; Voriconazole

Indexed keywords

ANTIFUNGAL AGENT; FLUCONAZOLE; PYRIMIDINE DERIVATIVE; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ARTICLE; BLOOD; COMPARATIVE STUDY; DRUG EFFECT; FUNGEMIA; HUMAN; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; ROMANIA; YEAST;

ANTIFUNGAL AGENTS; BLOOD; FLUCONAZOLE; FUNGEMIA; HUMANS; MICROBIAL SENSITIVITY TESTS; PYRIMIDINES; ROMANIA; TRIAZOLES; YEASTS;

CANDIDA;

EID: 80855139033     PISSN: 0301486X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11046-011-9455-1     Document Type: Article

References (22)

1. Pfaller MA, Diekema DJ, Gibbs DL et al. Results from the ARTEMIS DISK global antifungal surveillance study, 1997 to 2007: a 10. 5-year analysis of susceptibilities of Candida species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. J Clin Microbiol. 2010; 48(4): 1366-77.
2. Pfaller MA, Espinel-Ingroff A, Boyken L et al. Comparison of the broth microdilution (BMD) method of the European committee on antimicrobial susceptibility testing with the 24-hour CLSI BMD method for testing susceptibility of Candida species to fluconazole, posaconazole, and voriconazole by use of epidemiological cutoff values. J Clin Microbiol. 2011; 49(3): 845-50.
3. Lyon GM, Karatela S, Sunay S, et al. Antifungal susceptibility testing of Candida isolates from the Candida surveillance study. J Clin Microbiol. 2010; 48(4): 1270-5.
4. Ostrosky-Zeichner L, Rex JH, Pappas PG, et al. Antifungal susceptibility survey of 2000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother. 2003; 47(10): 3149-54.
5. Quindos G, Sanchez-Varga LO, Villar-Vidal M, et al. Activities of fluconazole and voriconazole against bloodstream isolates of Candidaglabrata and Candidakrusei: a 14-year study in a Spanish tertiary medical centre. Int J Antimicrob Agents. 2008; 31(3): 266-71.
6. Vermes A, Guchelaar HJ, Dankert J. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J Antimicrob Chemother. 2000; 46(2): 171-9.
7. Szejtli J. Past, present, and future of cyclodextrin research. Pure Appl Chem. 2004; 76(10): 1825-45.
8. Spulber M, Miron L, Mareş M, et al. Water soluble 5-FC complexes, preliminary pharmacological studies. J Incl Phenom Macrocycl Chem. 2009; 65: 431-5.
9. Miron L, Mareş M, Nǎstasǎ V, et al. Water soluble sulconazole-beta-cyclodextrin complex: physico-chemical characterization and preliminary pharmacological studies. J Incl Phenom Macrocycl Chem. 2009; 63: 159-62.
10. Mareş M, Ştefanache A, Popovici I, et al. Evaluation of the antifungal effect of a new propiconazole derivative against 64 yeast strains isolated from vaginal mycoses. Fungi Mycotox. 2007; 2: 83-7.
11. Goetz KA, Dix JD. Mode of action for reproductive and hepatic toxicity inferred from a genomic study of triazole antifungals. Toxicol Sci. 2009; 110(2): 449-62.
12. Chen P-J, Moore T, Nesnow S. Cytotoxic effects of propiconazole and its metabolites in mouse and human hepatoma cells and primary mouse hepatocytes. Toxicol In Vitro. 2008; 22: 1476-83.
13. World Health Organisation. The WHO recommended classification of pesticides by hazard and guidelines to classification. Geneva: WHO Press; 2010.
14. Pfizer Inc. Vfend (Voriconazole) Powder for oral suspension. Material safety data sheet; version 1. 2; 2007.
15. Rodriguez-Tudela JL, Arendrup MC, Barchiesi F, et al. EUCAST definitive document E Def 7. 1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. Clin Microbiol Infect. 2008; 14: 398-405.
16. Dannaoui E, Lortholary O, Raoux D, et al. Comparative in vitro activities of caspofungin and micafungin, determined using the method of the European committee on antimicrobial susceptibility testing, against yeast isolates obtained in France in 2005-2006. Antimicrob Agents Chemother. 2008; 52(2): 778-81.
17. Rodriguez-Tudela JL, Donnelly JP, Arendrup MC, et al. EUCAST technical note on fluconazole. Clin Microbiol Infect. 2008; 14(2): 193-5.
18. Espinel-Ingroff A, Pfaller M, Cantón E, et al. Emerging resistance to azoles and echinocandins: clinical relevance and laboratory detection. Curr Fungal Infect Rep. 2010; 4(3): 186-95.
19. Rodriguez-Tudela JL, Donnelly JP, Arendrup MC, et al. EUCAST technical note on voriconazole. Clin Microbiol Infect. 2008; 14(10): 985-7.
20. Kuhn DM, Ghannoum MA. Candida biofilms: antifungal resistance and emerging therapeutic options. Curr Opin Investig Drugs. 2004; 5: 186-97.
21. Pfaller MA, Diekema DJ, Gibbs DL et al. Geographic variation in the frequency of isolation and fluconazole and voriconazole susceptibilities of Candidaglabrata: an assessment from the ARTEMIS DISK global antifungal surveillance program. Diag Microbiol Infect Dis. 2010; 67(2): 162-71.
22. Sellami A, Sellami H, Neji S, et al. Antifungal susceptibility of bloodstream Candida isolates in Sfax Hospital: Tunisia. Mycopathol. 2010; 171(6): 417-22.